<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
        <title>JBJI - recent articles</title>


    <link rel="self" href="https://jbji.copernicus.org/articles/"/>
    <id>https://jbji.copernicus.org/articles/</id>
    <updated>2026-08-07T22:29:57+02:00</updated>
    <author>
        <name>Copernicus Publications</name>
    </author>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-489-2026</id>
            <title type="html">Isolation policies in musculoskeletal infection  care: time to move from tradition to evidence
            </title>
            <link href="https://doi.org/10.5194/jbji-11-489-2026"/>
            <summary type="html">
                &lt;b&gt;Isolation policies in musculoskeletal infection  care: time to move from tradition to evidence&lt;/b&gt;&lt;br&gt;
                Laura Bessems, Jolien Onsea, Marjan Wouthuyzen-Bakker, Irene K. Sigmund, Tristan Ferry, Richard Kuehl, Martin Clauss, Alex Soriano, Ricardo Sousa, Annette Schuermans, and Willem-Jan Metsemakers&lt;br&gt;
                    J. Bone Joint Infect., 11, 489&#8211;492, https://doi.org/10.5194/jbji-11-489-2026, 2026&lt;br&gt;
                We examined whether patients with musculoskeletal infections need to be separated in hospital. A review of published studies found no support for routine isolation or dedicated wards for infections without multidrug-resistant organisms when standard precautions are applied. An international survey showed wide variation in clinician attitudes. These findings highlight a gap between evidence and perception and support a more risk-based approach.
            </summary>
            <content type="html">
                &lt;b&gt;Isolation policies in musculoskeletal infection  care: time to move from tradition to evidence&lt;/b&gt;&lt;br&gt;
                Laura Bessems, Jolien Onsea, Marjan Wouthuyzen-Bakker, Irene K. Sigmund, Tristan Ferry, Richard Kuehl, Martin Clauss, Alex Soriano, Ricardo Sousa, Annette Schuermans, and Willem-Jan Metsemakers&lt;br&gt;
                    J. Bone Joint Infect., 11, 489&#8211;492, https://doi.org/10.5194/jbji-11-489-2026, 2026&lt;br&gt;
                <p>A recent scoping review found no evidence supporting routine ward-level isolation or dedicated septic wards for non-multidrug-resistant organism musculoskeletal infections when standard precautions are applied, whereas targeted measures remain appropriate for multidrug-resistant organisms. An international survey revealed wide variation in attitudes and a persistent belief in supporting evidence, highlighting a gap between evidence and perception and supporting a differentiated, risk-based approach to isolation.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-08-07T22:29:57+02:00</published>
            <updated>2026-08-07T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-479-2026</id>
            <title type="html">Culture-negative periprosthetic joint infection: an umbrella review of prevalence, diagnostic strategies, treatment, and methodological limitations
            </title>
            <link href="https://doi.org/10.5194/jbji-11-479-2026"/>
            <summary type="html">
                &lt;b&gt;Culture-negative periprosthetic joint infection: an umbrella review of prevalence, diagnostic strategies, treatment, and methodological limitations&lt;/b&gt;&lt;br&gt;
                Guido Bocchino, Giulio Maccauro, Andrea Zampoli, Rocco Papalia, Pier Francesco Indelli, Daniel Pérez-Prieto, and Javad Parvizi&lt;br&gt;
                    J. Bone Joint Infect., 11, 479&#8211;488, https://doi.org/10.5194/jbji-11-479-2026, 2026&lt;br&gt;
                The current umbrella review showed that prevalence, diagnostic performance of adjunctive molecular methods, treatment strategies, and outcomes vary substantially. Molecular diagnostics appear to be promising as adjunctive tools in selected cases, but their interpretation requires caution, and they do not resolve all uncertainties related to culture-negative periprosthetic joint infections.&amp;#160;
            </summary>
            <content type="html">
                &lt;b&gt;Culture-negative periprosthetic joint infection: an umbrella review of prevalence, diagnostic strategies, treatment, and methodological limitations&lt;/b&gt;&lt;br&gt;
                Guido Bocchino, Giulio Maccauro, Andrea Zampoli, Rocco Papalia, Pier Francesco Indelli, Daniel Pérez-Prieto, and Javad Parvizi&lt;br&gt;
                    J. Bone Joint Infect., 11, 479&#8211;488, https://doi.org/10.5194/jbji-11-479-2026, 2026&lt;br&gt;
                <p><strong>Purpose</strong>: Culture-negative periprosthetic joint infection (CN-PJI) poses a significant clinical challenge because antimicrobial selection relies on guesswork rather than robust clinical data. This umbrella review summarizes the prevalence of CN-PJI, diagnostic strategies (including molecular assays), treatment approaches, and outcomes. <strong>Methods</strong>: We conducted an umbrella review of published systematic reviews and meta-analyses on CN-PJI in adult hip and/or knee arthroplasties. Searches of major bibliographic databases were conducted in December 2025; two reviewers screened studies and extracted data on prevalence, reported risk factors, diagnostic criteria, use of molecular tests, specimen matrix (synovial fluid, periprosthetic tissue, and/or sonication fluid), surgical strategy, antimicrobial selection, and clinical outcomes (infection control or failure). Methodological quality was assessed with AMSTAR 2. <strong>Results</strong>: Nine reviews were included. Reported CN-PJI prevalence varied widely (11.0&amp;#8201;%&amp;#8211;63.6&amp;#8201;%), reflecting substantial heterogeneity in study populations, diagnostic definitions, microbiological workflows, and pre-analytical factors. Prior antibiotic exposure before sampling was repeatedly identified as an important contributor to culture negativity. Molecular diagnostics, predominantly NGS (next-generation sequencing)-based approaches, were evaluated in five out of nine reviews, with highly variable organism detection rates depending on assay type, specimen source, and study context. Where meta-analytic estimates were available, pooled sensitivity ranged from 0.81 to 0.93, and pooled specificity ranged from 0.92 to 0.97. Treatment strategies and outcome definitions were inconsistently reported across reviews; when extractable, two-stage exchange was the most frequently described surgical strategy. <strong>Conclusions</strong>: CN-PJI remains common and variable across settings. Molecular diagnostics improve pathogen detection but do not eliminate false negatives. Reported failure rates varied across reviews and appeared to be clinically relevant, although differences in outcome definitions, treatment protocols, and follow-up duration limited direct comparison.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-08-03T22:29:57+02:00</published>
            <updated>2026-08-03T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-463-2026</id>
            <title type="html">Timing from admission to debridement, antibiotic, and implant retention (DAIR) affects mortality risk in total hip prosthetic joint infections
            </title>
            <link href="https://doi.org/10.5194/jbji-11-463-2026"/>
            <summary type="html">
                &lt;b&gt;Timing from admission to debridement, antibiotic, and implant retention (DAIR) affects mortality risk in total hip prosthetic joint infections&lt;/b&gt;&lt;br&gt;
                Jack Legler, Samuel Morgan, Paul Beaulé, Hesham Abdelbary, George Grammatopoulos, and Simon Garceau&lt;br&gt;
                    J. Bone Joint Infect., 11, 463&#8211;477, https://doi.org/10.5194/jbji-11-463-2026, 2026&lt;br&gt;
                <span class="TextRun SCXO5318948 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXO5318948 BCX0">We studied patients with infected hip replacements to determine whether delays between hospital admission and&amp;#160; surgery affected recovery. By reviewing patient records from a specialty center, we found that longer delays were linked to a higher risk of death within 90 d. Older age, poorer overall health, and low blood levels also increased the chance of complications or repeat surgery. These results suggest that prompt treatment and careful health preparation can improve outcomes.</span></span><span class="EOP SCXO5318948 BCX0">&amp;#160;</span>
            </summary>
            <content type="html">
                &lt;b&gt;Timing from admission to debridement, antibiotic, and implant retention (DAIR) affects mortality risk in total hip prosthetic joint infections&lt;/b&gt;&lt;br&gt;
                Jack Legler, Samuel Morgan, Paul Beaulé, Hesham Abdelbary, George Grammatopoulos, and Simon Garceau&lt;br&gt;
                    J. Bone Joint Infect., 11, 463&#8211;477, https://doi.org/10.5194/jbji-11-463-2026, 2026&lt;br&gt;
                <p><strong>Introduction</strong>: Recent work in total knee arthroplasty (TKA) prosthetic joint infection (PJI) suggests that timing from hospital admission to DAIR (debridement, antibiotic, and implant retention) is a modifiable risk factor influencing treatment outcomes. The study assessed the impact of timing from admission to DAIR on clinical outcomes and treatment success in the total hip arthroplasty (THA) PJI population. <strong>Methods</strong>: A retrospective review was conducted at a specialized PJI tertiary referral centre. Patients who underwent DAIR for THA PJI between 2008 and 2021 with a minimum 2-year follow-up were included. The primary outcome was reoperation for recalcitrant PJI. Secondary outcomes included 90&amp;#8201;d readmission, 90&amp;#8201;d and 1-year mortality, and postoperative complications. Multivariate regression analysis identified factors associated with DAIR outcomes. <strong>Results</strong>: A total of 100 patients satisfied the inclusion criteria. The mean time from admission to DAIR was 46.4&amp;#8201;<span class="inline-formula">&amp;#177;</span>&amp;#8201;45.1&amp;#8201;h, and 52.0&amp;#8201;% required reoperation for recalcitrant PJI. Prolonged time from admission to DAIR was associated with increased 90&amp;#8201;d mortality (odds ratio or OR: 1.02, CI (confidence interval) 95&amp;#8201;%: 1.00&amp;#8211;1.03, <span class="inline-formula"><i>p</i>=</span>&amp;#8201;0.04). Increasing age was associated with greater 1-year mortality (OR: 1.06, CI 95&amp;#8201;%: 1.00&amp;#8211;1.12, <span class="inline-formula"><i>p</i>=</span>&amp;#8201;0.049). McPherson host grade C compared to grade A was associated with both greater 1-year mortality (OR: 12.75, CI 95&amp;#8201;%: 1.11&amp;#8211;146.09, <span class="inline-formula"><i>p</i>=</span>&amp;#8201;0.04) and postoperative complications (OR: 7.59, CI 95&amp;#8201;%: 1.22&amp;#8211;47.08, <span class="inline-formula"><i>p</i>=</span>&amp;#8201;0.03). McPherson extremity grade II versus grade I (OR: 3.28, CI 95&amp;#8201;%: 1.21&amp;#8211;8.92, <span class="inline-formula"><i>p</i>=</span>&amp;#8201;0.02) and revision THAs (OR: 0.15, CI 95&amp;#8201;%: 0.03&amp;#8211;0.72, <span class="inline-formula"><i>p</i>=</span>&amp;#8201;0.02) were associated with postoperative complications. Lower haemoglobin levels (OR: 1.04, CI 95&amp;#8201;%: 1.01&amp;#8211;1.07, <span class="inline-formula"><i>p</i>=</span>&amp;#8201;0.004) were associated with higher reoperation risk. <strong>Conclusion</strong>: In a DAIR-treated cohort, increased time from admission to surgery was associated with greater 90&amp;#8201;d mortality in THA PJI patients. Timely surgical intervention and optimization of modifiable risk factors are essential to improve outcomes.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-08-03T22:29:57+02:00</published>
            <updated>2026-08-03T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-453-2026</id>
            <title type="html">Rapid molecular culture versus conventional culture for periprosthetic joint infection: diagnostic performance and clinical relevance
            </title>
            <link href="https://doi.org/10.5194/jbji-11-453-2026"/>
            <summary type="html">
                &lt;b&gt;Rapid molecular culture versus conventional culture for periprosthetic joint infection: diagnostic performance and clinical relevance&lt;/b&gt;&lt;br&gt;
                Elizabeth Morreel, Paul Savelkoul, and Inge van Loo&lt;br&gt;
                    J. Bone Joint Infect., 11, 453&#8211;462, https://doi.org/10.5194/jbji-11-453-2026, 2026&lt;br&gt;
                Joint replacement infections are difficult to diagnose quickly because standard laboratory cultures can take days to weeks and may miss bacteria after antibiotic treatment. We evaluated a rapid molecular test using fluid from removed implants and found that it provided clinically useful results within hours. This approach may help doctors exclude infection sooner, reduce unnecessary antibiotic use, and improve patient care.
            </summary>
            <content type="html">
                &lt;b&gt;Rapid molecular culture versus conventional culture for periprosthetic joint infection: diagnostic performance and clinical relevance&lt;/b&gt;&lt;br&gt;
                Elizabeth Morreel, Paul Savelkoul, and Inge van Loo&lt;br&gt;
                    J. Bone Joint Infect., 11, 453&#8211;462, https://doi.org/10.5194/jbji-11-453-2026, 2026&lt;br&gt;
                <p><strong>Introduction</strong>: Periprosthetic joint infection (PJI) remains a major complication of joint arthroplasty, requiring rapid and accurate pathogen identification to guide appropriate antimicrobial therapy. Conventional culture is limited by prolonged turnaround times and reduced sensitivity, particularly following antibiotic exposure. This study evaluated the diagnostic performance and clinical relevance of Molecular Culture<sup>&amp;#174;</sup&gt; (MC), a rapid PCR-based assay, using sonication fluid (SF) obtained during revision arthroplasty. <strong>Methods</strong>: SF samples from patients undergoing hip or knee revision arthroplasty (2019&amp;#8211;2023) were retrospectively analysed. Patients were classified as PJI or non-PJI according to European Bone and Joint Infection Society criteria. MC results were compared with conventional SF culture. Positive percentage agreement (PPA) and negative percentage agreement (NPA) were calculated using culture as the reference standard. Clinical agreement was assessed using all available microbiological results and relevant clinical information, including recent antibiotic exposure. <strong>Results</strong>: A total of 203 SF samples from 172 patients were included. Analytical PPA and NPA of MC were 68.1&amp;#8201;% (95&amp;#8201;% CI, 59.9&amp;#8211;75.3) and 84.6&amp;#8201;% (95&amp;#8201;% CI, 73.9&amp;#8211;91.4), respectively. Following clinical correlation, PPA and NPA at patient level were 73.2&amp;#8201;% (95&amp;#8201;% CI, 64.9&amp;#8211;80.2) and 95.6&amp;#8201;% (95&amp;#8201;% CI, 85.2&amp;#8211;98.8), respectively. MC identified 11 additional clinically relevant pathogens and provided results within approximately 4&amp;#8201;h. <strong>Conclusions</strong>: MC demonstrated high clinically adjusted agreement and faster turnaround times than conventional culture, supporting its role as an adjunctive diagnostic tool for PJI. Its value may be greatest in patients with uncertain infection status or prior antimicrobial exposure, where rapid exclusion of infection could facilitate earlier optimisation of antimicrobial therapy.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-07-31T22:29:57+02:00</published>
            <updated>2026-07-31T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-441-2026</id>
            <title type="html">Bromelain and N-acetylcysteine (BromAc) as novel adjunctive therapy for prosthetic joint infection: a narrative review
            </title>
            <link href="https://doi.org/10.5194/jbji-11-441-2026"/>
            <summary type="html">
                &lt;b&gt;Bromelain and N-acetylcysteine (BromAc) as novel adjunctive therapy for prosthetic joint infection: a narrative review&lt;/b&gt;&lt;br&gt;
                Brendan Parnell and David Morris&lt;br&gt;
                    J. Bone Joint Infect., 11, 441&#8211;451, https://doi.org/10.5194/jbji-11-441-2026, 2026&lt;br&gt;
                Prosthetic joint infections are devastating complications of joint replacements, often resisting antibiotics because bacteria hide inside a protective slime called biofilm. We reviewed laboratory evidence on BromAc, a combination of a pineapple enzyme and a mucus-thinning agent that breaks down this slime. Early experiments suggest it can disrupt biofilm and improve antibiotic access, but key questions about safety, stability, and joint-specific testing must be answered before patient use.
            </summary>
            <content type="html">
                &lt;b&gt;Bromelain and N-acetylcysteine (BromAc) as novel adjunctive therapy for prosthetic joint infection: a narrative review&lt;/b&gt;&lt;br&gt;
                Brendan Parnell and David Morris&lt;br&gt;
                    J. Bone Joint Infect., 11, 441&#8211;451, https://doi.org/10.5194/jbji-11-441-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>:&amp;#160;Prosthetic joint infection (PJI) complicates 0.5&amp;#8201;%&amp;#8211;2.0&amp;#8201;% of total joint arthroplasties and remains the leading cause of implant failure. Bacterial biofilm confers marked antimicrobial resistance, and current strategies, including debridement, antibiotics, and implant retention (DAIR), carry a pooled failure rate of <span class="inline-formula">&amp;#8764;</span>&amp;#8201;36&amp;#8201;%. Novel biofilm-disrupting adjuncts are urgently needed. <strong>Purpose</strong>:&amp;#160;The aim is to examine preclinical evidence of bromelain and N-acetylcysteine (BromAc) as a combination antibiofilm therapy in PJI management and to critically appraise its translational readiness. <strong>Methods</strong>:&amp;#160;A narrative literature search was conducted for studies examining N-acetylcysteine, bromelain, and BromAc in the context of biofilm disruption on orthopaedic prosthetic materials. Eligible studies were appraised qualitatively for pathogen, substrate, exposure conditions, outcome measures, and methodological limitations to allow comparative interpretation rather than narrative summary alone. <strong>Results</strong>:&amp;#160;N-acetylcysteine demonstrates concentration-dependent antibiofilm activity, achieving approximately 50&amp;#8201;% biofilm reduction on polyethylene and 20&amp;#8201;% on titanium at minimum inhibitory concentrations, rising to 81.5&amp;#8201;% eradication of staphylococcal biofilms at higher concentrations in non-orthopaedic substrates. Bromelain achieves significant biofilm reduction from orthopaedic hardware via proteolytic degradation of extracellular polymeric substance protein scaffolds. In the principal proof-of-concept study on hernia mesh, BromAc achieved <span class="inline-formula">></span>&amp;#8201;80&amp;#8201;% biofilm removal (quantified by crystal violet biomass reduction) across three <i>Pseudomonas aeruginosa</i&gt; strains, exceeding either agent alone; activity against staphylococci has been reported in unpublished sponsor data but is not yet independently replicated in peer-reviewed orthopaedic models. <strong>Conclusions</strong>:&amp;#160;BromAc represents a mechanistically rational adjunctive therapy for PJI, targeting distinct biofilm matrix components. However, current evidence is largely preclinical, much of it derived from non-orthopaedic substrates and pathogens, and several supporting datasets are unpublished sponsor data. Important translational gaps remain in peer-reviewed staphylococcal validation on prosthetic materials, formulation stability (particularly the susceptibility of N-acetylcysteine to oxidation in aqueous solution), intra-articular safety with respect to cartilage and osseointegration, and the absence of an in vivo orthopaedic implant model. These limitations must be resolved before clinical translation can be responsibly considered.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-07-28T22:29:57+02:00</published>
            <updated>2026-07-28T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-431-2026</id>
            <title type="html">Sonication fluid cultures enhance pathogen identification in fracture-related-infection (FRI)
            </title>
            <link href="https://doi.org/10.5194/jbji-11-431-2026"/>
            <summary type="html">
                &lt;b&gt;Sonication fluid cultures enhance pathogen identification in fracture-related-infection (FRI)&lt;/b&gt;&lt;br&gt;
                Anas Zouitni, Erlangga Yusuf, Jakob van Oldenrijk, Tjebbe Hagenaars, Peter D. Croughs, P. Koen Bos, Denise Eygendaal, and Ewout S. Veltman&lt;br&gt;
                    J. Bone Joint Infect., 11, 431&#8211;440, https://doi.org/10.5194/jbji-11-431-2026, 2026&lt;br&gt;
                This study explores the diagnostic value of sonication fluid culture (SFC) as an adjunct to conventional diagnostic methods for fracture-related infection (FRI). SFC improves pathogen detection and contributes to more accurate diagnosis of FRI. In approximately 6 % to 16 % of confirmed FRI cases, SFC influenced FRI management. These findings support the routine use of SFC alongside standard tissue cultures, with adequate sampling according to protocol.
            </summary>
            <content type="html">
                &lt;b&gt;Sonication fluid cultures enhance pathogen identification in fracture-related-infection (FRI)&lt;/b&gt;&lt;br&gt;
                Anas Zouitni, Erlangga Yusuf, Jakob van Oldenrijk, Tjebbe Hagenaars, Peter D. Croughs, P. Koen Bos, Denise Eygendaal, and Ewout S. Veltman&lt;br&gt;
                    J. Bone Joint Infect., 11, 431&#8211;440, https://doi.org/10.5194/jbji-11-431-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>: Sonication fluid culture&amp;#160;(SFC) of osteosynthesis material may be a valuable adjunct tool to diagnose fracture-related infection&amp;#160;(FRI). This study aims to evaluate the added diagnostic value of SFC as a diagnostic tool. The diagnostic value of SFC was assessed by evaluating its impact on confirming microbiological results and changing diagnosis. <strong>Methods</strong>: We analysed patients undergoing osteosynthesis hardware removal between&amp;#160;2012 and&amp;#160;2021. We categorized patients using FRI consensus criteria: suspected FRI or confirmed FRI. The sensitivity and specificity of tissue cultures and SFC were assessed. The added value of SFC was determined as the number of cases where SFC was essential for confirming FRI and the influence on antibiotic therapy selection. <strong>Results</strong>: We included 96&amp;#160;patients with three or more tissue cultures. Based on diagnosis without SFC, we found 14&amp;#160;aseptic, 35&amp;#160;suggestive FRI cases, and 47&amp;#160;confirmed FRI cases. Following SFC results, four&amp;#160;cases changed diagnosis from aseptic to suggestive FRI, and three&amp;#160;cases changed from suggestive FRI to confirmed FRI. The sensitivity of tissue culture was 74&amp;#8201;%, and the specificity was 98&amp;#8201;%. The sensitivity of SFC was 84&amp;#8201;%, and the specificity was 83&amp;#8201;%. Combining tissue cultures with SFC significantly increased sensitivity compared with tissue cultures alone, from 74&amp;#8201;% to 88&amp;#8201;% (<span class="inline-formula"><i>p</i><0.001</span>). In 21&amp;#160;confirmed FRIs (42&amp;#8201;%), SFC results were concordant with tissue cultures and would not alter FRI management. SFC detected an additional virulent pathogen in three&amp;#160;confirmed FRIs (6&amp;#8201;%) and low-virulent pathogens in eight&amp;#160;confirmed FRIs (16&amp;#8201;%) which could influence the antibiotic regimen.</p&gt;        <p><strong>Conclusions:</strong&gt; SFC plays a significant role in diagnosing FRI by enhancing pathogen detection. SFC may influence FRI management in approximately 6&amp;#8201;% to 16&amp;#8201;% of confirmed FRI. In every FRI, an adequate number of cultures according to protocol should be obtained, and SFC should also be performed.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-07-20T22:29:57+02:00</published>
            <updated>2026-07-20T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-413-2026</id>
            <title type="html">Management and outcomes of culture-negative periprosthetic joint infection: a systematic  review and meta-analysis
            </title>
            <link href="https://doi.org/10.5194/jbji-11-413-2026"/>
            <summary type="html">
                &lt;b&gt;Management and outcomes of culture-negative periprosthetic joint infection: a systematic  review and meta-analysis&lt;/b&gt;&lt;br&gt;
                Farzad Pourghazi, Seyed Mohammad Amin Alavi, Takahiro Matsuo, Georges Baaklini, Matthew P. Abdel, Aaron J. Tande, and Elie F. Berbari&lt;br&gt;
                    J. Bone Joint Infect., 11, 413&#8211;430, https://doi.org/10.5194/jbji-11-413-2026, 2026&lt;br&gt;
                Culture-negative periprosthetic joint infection (CN-PJI) remains a diagnostic and therapeutic challenge. In this systematic review and meta-analysis of 27 studies (1399 patients), pooled success was 83.6&amp;#8201;%, failure was 17.2&amp;#8201;%, and mortality was 2.4&amp;#8201;%. Outcomes were better with exchange arthroplasty than debridement, antimicrobials, and implant retention (DAIR). Antibiotic regimens were heterogeneous. Overall, CN-PJI may have favorable outcomes, but standardized prospective studies are needed.
            </summary>
            <content type="html">
                &lt;b&gt;Management and outcomes of culture-negative periprosthetic joint infection: a systematic  review and meta-analysis&lt;/b&gt;&lt;br&gt;
                Farzad Pourghazi, Seyed Mohammad Amin Alavi, Takahiro Matsuo, Georges Baaklini, Matthew P. Abdel, Aaron J. Tande, and Elie F. Berbari&lt;br&gt;
                    J. Bone Joint Infect., 11, 413&#8211;430, https://doi.org/10.5194/jbji-11-413-2026, 2026&lt;br&gt;
                <p><strong>Introduction</strong>: Culture-negative periprosthetic joint infection&amp;#160;(CN-PJI) remains a major diagnostic and therapeutic challenge because antimicrobial and surgical management are often empirical. <strong>Methods</strong>: We performed a systematic review and meta-analysis to evaluate treatment strategies and outcomes of CN-PJI. MEDLINE and Scopus were searched through 3&amp;#160;July&amp;#160;2025, and 27&amp;#160;cohort studies including 1399&amp;#160;CN-PJI patients were included. <strong>Results</strong>: Random-effect meta-analyses showed a pooled treatment success proportion of 83.6&amp;#8201;% (95&amp;#8201;%&amp;#160;CI, 78.2&amp;#8211;87.9), a pooled failure proportion of 17.2&amp;#8201;% (95&amp;#8201;%&amp;#160;CI, 12.6&amp;#8211;22.9), and a pooled mortality proportion of 2.4&amp;#8201;% (95&amp;#8201;%&amp;#160;CI, 1.3&amp;#8211;4.6). Subgroup analyses demonstrated lower success and higher failure with debridement, antibiotics, and implant retention compared with one-stage and two-stage exchange arthroplasty. Hip CN-PJI showed higher reported success than knee CN-PJI. Antimicrobial regimens were highly heterogeneous and were not suitable for pooled analysis. <strong>Conclusion</strong>: Overall, CN-PJI may have favorable outcomes, particularly with exchange arthroplasty, but prospective studies with standardized definitions and treatment reporting are needed.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-07-14T22:29:57+02:00</published>
            <updated>2026-07-14T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-401-2026</id>
            <title type="html">Management of fracture-related infection in low-resource settings in Africa: recommendations and guidelines from an international expert group
            </title>
            <link href="https://doi.org/10.5194/jbji-11-401-2026"/>
            <summary type="html">
                &lt;b&gt;Management of fracture-related infection in low-resource settings in Africa: recommendations and guidelines from an international expert group&lt;/b&gt;&lt;br&gt;
                Loïc Fonkoué, Elizabeth K. Tissingh, Leonard C. Marais, Mbonisi Malaba, Kidanemariam Abrha, Jamie Ferguson, Mario Morgenstern, Olivier Cornu, Maritz Laubscher, Randy Buzisa Mbuku, George W. Galiwango, Matthijs Botman, Justyna Wojno, Mtebe Venance Majigo, Claude Martin Jr., William James Harrison, Alexander Thomas Schade, Kebba Marenah, Malvern Nyamutora, Phiona E. Namale, Vuyisa Mdingi, and Martin McNally&lt;br&gt;
                    J. Bone Joint Infect., 11, 401&#8211;411, https://doi.org/10.5194/jbji-11-401-2026, 2026&lt;br&gt;
                Fracture-related infection is a serious problem after broken bones, especially in low-resource settings where specialist care and services are limited. An international expert group developed practical recommendations adapted to these realities. The guidance focuses on early fracture care, simple diagnostic approaches, flexible antibiotic use, affordable local treatments, good soft tissue management, and teamwork, aiming to improve safe and effective care in resource-limited environments.
            </summary>
            <content type="html">
                &lt;b&gt;Management of fracture-related infection in low-resource settings in Africa: recommendations and guidelines from an international expert group&lt;/b&gt;&lt;br&gt;
                Loïc Fonkoué, Elizabeth K. Tissingh, Leonard C. Marais, Mbonisi Malaba, Kidanemariam Abrha, Jamie Ferguson, Mario Morgenstern, Olivier Cornu, Maritz Laubscher, Randy Buzisa Mbuku, George W. Galiwango, Matthijs Botman, Justyna Wojno, Mtebe Venance Majigo, Claude Martin Jr., William James Harrison, Alexander Thomas Schade, Kebba Marenah, Malvern Nyamutora, Phiona E. Namale, Vuyisa Mdingi, and Martin McNally&lt;br&gt;
                    J. Bone Joint Infect., 11, 401&#8211;411, https://doi.org/10.5194/jbji-11-401-2026, 2026&lt;br&gt;
                <p><strong>Background:</strong&gt; Fracture-related infection (FRI) represents one of the most challenging complications in trauma care and disproportionately affects patients in low-resource settings, where diagnostic capacity, surgical infrastructure, and access to microbiology and reconstructive expertise are limited. <strong>Methods:</strong&gt; An expert group was convened through the African Bone and Joint Infection Network (ABJIN) under the auspices of the European Bone and Joint Infection Society (EBJIS) and with support from the AO Alliance. Recommendations were developed through a three-step process: (1) a two-part survey assessing current practice and priority needs among clinicians from African countries, (2) an in-person multidisciplinary consensus meeting during the COSECSA Congress (Harare, 2024), and (3) an iterative collaborative review by a wider panel of clinicians from 14 countries. <strong>Results:</strong&gt; The group produced context-adapted recommendations covering prevention, terminology, diagnosis, investigations, holistic patient optimization, antimicrobial therapy, local antibiotic delivery, and surgical management of FRI in low-resource settings. Key themes include the following: management of open fractures; diagnostic pathways prioritizing clinical criteria and intra-operative sampling; antimicrobial strategies reflecting local microbiology and drug availability; affordable local antibiotic carriers; and the importance of soft-tissue management, multidisciplinary collaboration, and centralization of complex cases. Barriers specific to low-resource settings &amp;#8211; delayed presentation, restricted microbiology services, limited implant availability, and high burdens of comorbidities &amp;#8211; were integrated into the recommendations. <strong>Conclusion:</strong&gt; These consensus-based, context-specific recommendations provide practical guidance for FRI in low-resource settings. They aim to support clinicians in delivering safe, cost-effective care, accepting structural limitations while promoting standardization and audit. Further clinical research from low- and middle-income countries is needed to strengthen the evidence base and refine these recommendations.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-07-09T22:29:57+02:00</published>
            <updated>2026-07-09T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-395-2026</id>
            <title type="html">Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting
            </title>
            <link href="https://doi.org/10.5194/jbji-11-395-2026"/>
            <summary type="html">
                &lt;b&gt;Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting&lt;/b&gt;&lt;br&gt;
                Alexander J. Richards, Ammara Asif, Monica Ivan, Patrick J. Lillie, Gavin Barlow, and Chloe Walsh&lt;br&gt;
                    J. Bone Joint Infect., 11, 395&#8211;400, https://doi.org/10.5194/jbji-11-395-2026, 2026&lt;br&gt;
                Fungal infection can be difficult to treat, requiring long periods of hospitalisation. Rezafungin is a promising new antifungal medication that can be used to treat complex, deep-seated fungal infection. We examine the reported use of rezafungin in managing fungal infection of the bones and joints in an outpatient setting. Our case helps to provide further experience in the use of rezafungin as a powerful tool in helping patients get out of hospital and avoid further admissions.
            </summary>
            <content type="html">
                &lt;b&gt;Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting&lt;/b&gt;&lt;br&gt;
                Alexander J. Richards, Ammara Asif, Monica Ivan, Patrick J. Lillie, Gavin Barlow, and Chloe Walsh&lt;br&gt;
                    J. Bone Joint Infect., 11, 395&#8211;400, https://doi.org/10.5194/jbji-11-395-2026, 2026&lt;br&gt;
                <p>Bone and joint infections secondary to <i>Candida</i&gt; species are associated with high morbidity and mortality, requiring extended courses of antifungal therapy, with parenteral medications being first-line therapy. The reported use of antifungals in outpatient parenteral antimicrobial therapy (OPAT) for deep-seated bone and joint infections is limited. We report and discuss the use of rezafungin, a novel long-acting echinocandin, in an OPAT setting for spondylodiscitis secondary to <i>Candida albicans</i>.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-07-06T22:29:57+02:00</published>
            <updated>2026-07-06T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-387-2026</id>
            <title type="html">Changes in systemic immune&#8211;inflammation index predict periprosthetic joint infection after hemiarthroplasty in elderly patients
            </title>
            <link href="https://doi.org/10.5194/jbji-11-387-2026"/>
            <summary type="html">
                &lt;b&gt;Changes in systemic immune–inflammation index predict periprosthetic joint infection after hemiarthroplasty in elderly patients&lt;/b&gt;&lt;br&gt;
                Emre Bilgin, Onur Gultekin, Murat Kilic, Umit Burak Alparslan, Mehmet Berke Yusan, and Ahmet Onur Akpolat&lt;br&gt;
                    J. Bone Joint Infect., 11, 387&#8211;394, https://doi.org/10.5194/jbji-11-387-2026, 2026&lt;br&gt;
                We looked at whether routine blood tests could help identify patients at higher risk of infection after hip fracture surgery. Using data from a large group of older patients, we found that higher inflammation levels after surgery, especially when they increased compared to before surgery, were linked to a greater risk of infection. This suggests that simple and widely available tests may help clinicians recognize high-risk patients earlier and guide closer follow-up.
            </summary>
            <content type="html">
                &lt;b&gt;Changes in systemic immune–inflammation index predict periprosthetic joint infection after hemiarthroplasty in elderly patients&lt;/b&gt;&lt;br&gt;
                Emre Bilgin, Onur Gultekin, Murat Kilic, Umit Burak Alparslan, Mehmet Berke Yusan, and Ahmet Onur Akpolat&lt;br&gt;
                    J. Bone Joint Infect., 11, 387&#8211;394, https://doi.org/10.5194/jbji-11-387-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>: Periprosthetic joint infection&amp;#160;(PJI) remains a devastating complication after hemiarthroplasty in elderly patients with femoral neck fractures. Early identification of high-risk patients is important. The systemic immune&amp;#8211;inflammation index&amp;#160;(SII), calculated as platelet&amp;#8201;<span class="inline-formula">&amp;#215;</span>&amp;#8201;neutrophil&amp;#8201;<span class="inline-formula"><math xmlns="http://www.w3.org/1998/Math/MathML" id="M2" display="inline" overflow="scroll" dspmath="mathml"><mo>/</mo></math><span><svg:svg xmlns:svg="http://www.w3.org/2000/svg" width="8pt" height="14pt" class="svg-formula" dspmath="mathimg" md5hash="527256ea34e0af356380afd605ccefc0"><svg:image xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jbji-11-387-2026-ie00001.svg" width="8pt" height="14pt" src="jbji-11-387-2026-ie00001.png"/></svg:svg></span></span>&amp;#8201;lymphocyte count, is a marker of systemic inflammation, although its role in this population remains unclear. <strong>Methods</strong>: This retrospective single-centre study included patients aged <span class="inline-formula">&amp;#8805;65</span>&amp;#160;years who underwent hemiarthroplasty between&amp;#160;2015 and&amp;#160;2025. Preoperative and postoperative day-5 SII values were calculated from routine blood tests. <span class="inline-formula">&amp;#916;</span>SII was defined as the difference between postoperative and preoperative values. The primary outcome was PJI within 1 year after surgery. Logistic regression and receiver operating characteristic&amp;#160;(ROC) analyses were performed. <strong>Results</strong>: A total of 976&amp;#160;patients were included, of whom 47&amp;#160;(4.8&amp;#8201;%) developed PJI. Postoperative SII values were significantly higher in patients with PJI, whereas preoperative SII was not associated with infection risk. In multivariable analysis, postoperative SII remained independently associated with PJI (OR&amp;#160;1.195, 95&amp;#8201;%&amp;#160;CI 1.144&amp;#8211;1.248, <span class="inline-formula"><i>p</i><0.001</span>). <span class="inline-formula">&amp;#916;</span>SII was also independently associated with PJI (OR&amp;#160;1.124, 95&amp;#8201;%&amp;#160;CI 1.085&amp;#8211;1.164, <span class="inline-formula"><i>p</i><0.001</span>). ROC analysis demonstrated good discriminatory performance for postoperative SII (AUC&amp;#160;0.882), with an optimal cut-off value of&amp;#160;2118. In contrast, <span class="inline-formula">&amp;#916;</span>SII showed moderate discriminatory performance (AUC&amp;#160;0.764), with an optimal cut-off value of&amp;#160;656. <strong>Conclusions</strong>: Postoperative SII and <span class="inline-formula">&amp;#916;</span>SII were independently associated with PJI after hemiarthroplasty. SII may aid early postoperative risk stratification and clinical decision-making when interpreted alongside clinical findings.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-07-03T22:29:57+02:00</published>
            <updated>2026-07-03T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-373-2026</id>
            <title type="html">Integrating molecular and conventional diagnostics in native vertebral osteomyelitis: a narrative review
            </title>
            <link href="https://doi.org/10.5194/jbji-11-373-2026"/>
            <summary type="html">
                &lt;b&gt;Integrating molecular and conventional diagnostics in native vertebral osteomyelitis: a narrative review&lt;/b&gt;&lt;br&gt;
                Farzad Pourghazi, Omar Mahmoud, Francesco Petri, Said El Zein, Gina A. Suh, Takahiro Matsuo, Andrea Gori, Audrey N. Schuetz, and Elie F. Berbari&lt;br&gt;
                    J. Bone Joint Infect., 11, 373&#8211;385, https://doi.org/10.5194/jbji-11-373-2026, 2026&lt;br&gt;
                Native vertebral osteomyelitis, a spinal bone infection, is difficult to diagnose, and delays can worsen outcomes. This review examines how traditional laboratory tests and newer genetic techniques can be integrated to improve identification of the responsible microorganism. We show that combining these approaches within the diagnostic pathway may increase accuracy and support earlier diagnosis, enabling more timely and informed treatment decisions.
            </summary>
            <content type="html">
                &lt;b&gt;Integrating molecular and conventional diagnostics in native vertebral osteomyelitis: a narrative review&lt;/b&gt;&lt;br&gt;
                Farzad Pourghazi, Omar Mahmoud, Francesco Petri, Said El Zein, Gina A. Suh, Takahiro Matsuo, Andrea Gori, Audrey N. Schuetz, and Elie F. Berbari&lt;br&gt;
                    J. Bone Joint Infect., 11, 373&#8211;385, https://doi.org/10.5194/jbji-11-373-2026, 2026&lt;br&gt;
                <p>Native vertebral osteomyelitis (NVO) remains a diagnostic challenge due to its non-specific presentation and the limited sensitivity of culture-based methods. Blood cultures and image-guided biopsies are considered the diagnostic standards, but their yield is often low, especially in patients who have received prior antibiotics or are infected with fastidious microorganisms. Recent molecular techniques, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), have improved pathogen detection and enabled more targeted antimicrobial therapy.</p&gt;        <p>In this narrative review, we summarize the diagnostic methods used in NVO, including conventional microbiological and molecular approaches, and present their strengths and limitations based on previous studies. We particularly focus on situations where molecular diagnostic techniques, such as 16S rRNA PCR, NGS, and microbial cell-free DNA testing, outperform traditional culture-based methods in sensitivity, while their specificity may be comparatively lower. Combining these molecular tools with standard diagnostic procedures may improve pathogen detection, guide targeted treatment, and enhance diagnostic accuracy in culture-negative or antibiotic-pretreated cases. Understanding the advantages and limitations of each diagnostic method can help clinicians to choose the most appropriate testing strategy, reduce diagnostic delays, and improve patient management in suspected NVO.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-29T22:29:57+02:00</published>
            <updated>2026-06-29T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-363-2026</id>
            <title type="html">Neutrophil extracellular trap (NET)-related index as an indicator of periprosthetic joint infection
            </title>
            <link href="https://doi.org/10.5194/jbji-11-363-2026"/>
            <summary type="html">
                &lt;b&gt;Neutrophil extracellular trap (NET)-related index as an indicator of periprosthetic joint infection&lt;/b&gt;&lt;br&gt;
                Tingrun Cui, Yongjian Liang, Zeyu Feng, Libo Hao, Guoqiang Zhang, Ming Ni, Jing Sheng, Dihua Shangguan, Jiying Chen, and Jun Fu&lt;br&gt;
                    J. Bone Joint Infect., 11, 363&#8211;371, https://doi.org/10.5194/jbji-11-363-2026, 2026&lt;br&gt;
                Periprosthetic joint infection is the most challenging complication following arthroplasty. This study, utilizing clinically obtained synovial fluid specimens, confirmed the unique value of neutrophil extracellular traps and their constituent components in the diagnosis of periprosthetic joint infection, thereby enabling further precision in the diagnosis of periprosthetic joint infection and reducing the severe consequences associated with it.
            </summary>
            <content type="html">
                &lt;b&gt;Neutrophil extracellular trap (NET)-related index as an indicator of periprosthetic joint infection&lt;/b&gt;&lt;br&gt;
                Tingrun Cui, Yongjian Liang, Zeyu Feng, Libo Hao, Guoqiang Zhang, Ming Ni, Jing Sheng, Dihua Shangguan, Jiying Chen, and Jun Fu&lt;br&gt;
                    J. Bone Joint Infect., 11, 363&#8211;371, https://doi.org/10.5194/jbji-11-363-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>: Periprosthetic joint infection (PJI) is a devastating complication of arthroplasty and is difficult to diagnose accurately. This study aims to explore the value of neutrophil extracellular traps in synovial fluid (SF-NETs, web-like structures released by neutrophils as a critical innate immune response) for diagnosing PJI. <strong>Methods</strong>: A retrospective cohort study was conducted, enrolling post-arthroplasty subjects from January&amp;#160;2018 to December&amp;#160;2023. Three components of SF-NETs (cell-free double-strand DNA, SF-dsDNA; citrullinated histone H3, SF-CitH3; SF-Nucleosome) and SF-NETs<span class="inline-formula"><sub>1+</sub></span&gt; (positive with one out of the three NET components), SF-NETs<span class="inline-formula"><sub>2+</sub></span&gt; (positive with two out of the three NET components), white blood cell count (SF-WBC), polymorphonuclear cell percentage (SF-PMN&amp;#8201;%), neutrophil count in SF (SF-PMN), microbiological examinations (Culture) and infection-related systemic indices were evaluated. <strong>Results</strong>: A total of 64 of 153 included subjects were diagnosed as PJI. SF-dsDNA and SF-CitH3 had significantly higher levels in the PJI group compared to the non-PJI group (<span class="inline-formula"><i>P</i></span>&amp;#8201;<span class="inline-formula"><</span>&amp;#8201;0.001) and showed positive correlations with SF-WBC, SF-PMN&amp;#8201;% and SF-PMN (0.4&amp;#8201;<span class="inline-formula"><</span>&amp;#8201;<span class="inline-formula"><i>&amp;#961;</i></span>&amp;#8201;<span class="inline-formula"><</span>&amp;#8201;0.7), while SF-Nucleosome had no significant difference. Sensitivity and specificity of SF-NETs<span class="inline-formula"><sub>1+</sub></span>, SF-NETs<span class="inline-formula"><sub>2+</sub></span&gt; and Culture were 82.2&amp;#8201;% and 78.7&amp;#8201;%, 59.4&amp;#8201;% and 95.5&amp;#8201;%, and 54.1&amp;#8201;% and 86.8&amp;#8201;%, respectively. The NET related index (NETRI) was defined as 10.529&amp;#8201;<span class="inline-formula">&amp;#215;</span>&amp;#8201;SF-NETs<span class="inline-formula"><math xmlns="http://www.w3.org/1998/Math/MathML" id="M11" display="inline" overflow="scroll" dspmath="mathml"><mrow><msub><mi/><mrow><mn mathvariant="normal">1</mn><mo>+</mo></mrow></msub><mo>+</mo></mrow></math><span><svg:svg xmlns:svg="http://www.w3.org/2000/svg" width="20pt" height="10pt" class="svg-formula" dspmath="mathimg" md5hash="2780eb837f845df1ea71b72123ea6c7f"><svg:image xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jbji-11-363-2026-ie00001.svg" width="20pt" height="10pt" src="jbji-11-363-2026-ie00001.png"/></svg:svg></span></span>&amp;#8201;28.114&amp;#8201;<span class="inline-formula">&amp;#215;</span>&amp;#8201;SF-PMN&amp;#8201;% <span class="inline-formula">+</span&gt; 8.210&amp;#8201;<span class="inline-formula">&amp;#215;</span>&amp;#8201;Culture-1.452, with the area under the receiver operating characteristic curve of 0.922, making it a novel indicator. <strong>Conclusions</strong>: SF-NETs<span class="inline-formula"><sub>1+</sub></span&gt; and SF-NETs<span class="inline-formula"><sub>2+</sub></span&gt; may serve respectively in the screening and exclusion of PJI. NETRI represented a new discriminator for PJI diagnosis.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-22T22:29:57+02:00</published>
            <updated>2026-06-22T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-355-2026</id>
            <title type="html">Gram-negative prosthetic joint infections: a  retrospective multicentre European study of  incidence, risk factors, and treatment outcomes
            </title>
            <link href="https://doi.org/10.5194/jbji-11-355-2026"/>
            <summary type="html">
                &lt;b&gt;Gram-negative prosthetic joint infections: a  retrospective multicentre European study of  incidence, risk factors, and treatment outcomes&lt;/b&gt;&lt;br&gt;
                Ernest Famada Arboix, Arnaud Fischbacher, Matteo Carlo Maria Ferrari, Olivier Borens, and Daniel Pérez-Prieto&lt;br&gt;
                    J. Bone Joint Infect., 11, 355&#8211;361, https://doi.org/10.5194/jbji-11-355-2026, 2026&lt;br&gt;
                Gram-negative prosthetic joint infections are challenging. Robust European multicentre data remain limited. This study provides contemporary epidemiological and microbiological data from three tertiary centers across three European countries. We identify patient risk profiles and pathogen-related differences in treatment success. These findings offer novel, practical evidence to guide individualized management of gram-negative prosthetic joint infection (PJI).
            </summary>
            <content type="html">
                &lt;b&gt;Gram-negative prosthetic joint infections: a  retrospective multicentre European study of  incidence, risk factors, and treatment outcomes&lt;/b&gt;&lt;br&gt;
                Ernest Famada Arboix, Arnaud Fischbacher, Matteo Carlo Maria Ferrari, Olivier Borens, and Daniel Pérez-Prieto&lt;br&gt;
                    J. Bone Joint Infect., 11, 355&#8211;361, https://doi.org/10.5194/jbji-11-355-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>: Gram-negative&amp;#160;(GN) bacteria are an increasingly recognized cause of prosthetic joint infection&amp;#160;(PJI), accounting for 10&amp;#8201;%&amp;#8211;20&amp;#8201;% of cases. However, epidemiological data from European centres remain limited. This study aimed to evaluate the incidence, risk factors, microbiological profile, and treatment outcomes of GN PJI in several European tertiary referral hospitals. <strong>Methods</strong>: We conducted a retrospective multicentre study including all culture-positive hip and knee PJIs diagnosed between&amp;#160;2014 and&amp;#160;2018 at three tertiary hospitals in Italy, Spain, and Switzerland. Demographic characteristics, comorbidities, surgical management, microbiological data including antimicrobial susceptibility, and treatment outcomes were analysed. Treatment success was defined as absence of persistent or recurrent infection requiring additional surgery, prosthesis removal, infection-related mortality, or long-term suppressive antibiotic therapy. <strong>Results</strong>: Among 780&amp;#160;confirmed PJIs, 71&amp;#160;(9.1&amp;#8201;%) were caused by GN&amp;#160;bacteria. The most frequent pathogens were polymicrobial infections (29.6&amp;#8201;%), <i>Escherichia coli</i&gt; (25.4&amp;#8201;%), and <i>Pseudomonas aeruginosa</i&gt; (19.7&amp;#8201;%). GN PJI mainly affected elderly patients (median age 74&amp;#160;years), females (60.6&amp;#8201;%), and those with comorbidities such as diabetes mellitus (32.4&amp;#8201;%) and those who are overweight/obese (62&amp;#8201;%). Hip infections were more common than knee infections (59.2&amp;#8201;% vs.&amp;#160;40.8&amp;#8201;%). Overall treatment success was 89&amp;#8201;%. Two-stage revision showed the highest success rate of 94.8&amp;#8201;% compared with one-stage exchange (88&amp;#8201;%) and DAIR (81&amp;#8201;%). Ciprofloxacin was used in 72&amp;#8201;% of cases. <strong>Conclusions</strong>: GN PJI incidence was comparable to that of previous reports. These infections occur more often in elderly patients with comorbidities. Two-stage revision remains the most effective surgical strategy, and ciprofloxacin continues to be a key component of antimicrobial therapy for susceptible GN&amp;#160;infections.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-19T22:29:57+02:00</published>
            <updated>2026-06-19T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-343-2026</id>
            <title type="html">Intrawound vancomycin powder in orthopaedic surgery after the VPIP trial: a critical reappraisal of efficacy, dosing, application plane, and antimicrobial stewardship
            </title>
            <link href="https://doi.org/10.5194/jbji-11-343-2026"/>
            <summary type="html">
                &lt;b&gt;Intrawound vancomycin powder in orthopaedic surgery after the VPIP trial: a critical reappraisal of efficacy, dosing, application plane, and antimicrobial stewardship&lt;/b&gt;&lt;br&gt;
                Felix Werneburg, Alexander Zeh, Natalia Gutteck, and Karl-Stefan Delank&lt;br&gt;
                    J. Bone Joint Infect., 11, 343&#8211;354, https://doi.org/10.5194/jbji-11-343-2026, 2026&lt;br&gt;
                For over a decade, orthopaedic surgeons have sprinkled vancomycin powder into surgical wounds to prevent infection. New large randomised trials show this is ineffective in hip and knee replacements, though possibly useful in high-risk fracture surgery and infected revision cases. Based on these findings and international guidelines, we propose a framework that identifies specifically in which operations this antibiotic powder may still have a role and in which it should be avoided.
            </summary>
            <content type="html">
                &lt;b&gt;Intrawound vancomycin powder in orthopaedic surgery after the VPIP trial: a critical reappraisal of efficacy, dosing, application plane, and antimicrobial stewardship&lt;/b&gt;&lt;br&gt;
                Felix Werneburg, Alexander Zeh, Natalia Gutteck, and Karl-Stefan Delank&lt;br&gt;
                    J. Bone Joint Infect., 11, 343&#8211;354, https://doi.org/10.5194/jbji-11-343-2026, 2026&lt;br&gt;
                <p>Topical intrawound vancomycin powder has been widely adopted in orthopaedic surgery as an adjunct for the prevention of surgical site infection (SSI) and periprosthetic joint infection (PJI). Retrospective cohorts and derived meta-analyses have long suggested a consistent benefit, and the technique became established practice at many institutions. Over the past 5&amp;#160;years, prospective randomised evidence has added an important corrective to this picture. The VPIP trial (Saba et al., 2025) randomised 1901 high-risk patients undergoing primary hip or knee arthroplasty across 17 US centres and found no benefit of vancomycin, dilute povidone-iodine, or their combination over saline for any 3-month infection endpoint; a biostatistical projection to 80&amp;#8201;000 patients left the number needed to treat near 500, and enrolment was closed for statistical futility. The VANCO trial in high-risk tibial fractures (O'Toole et al., 2021) narrowly missed its primary endpoint (<span class="inline-formula"><i>P</i>=0.06</span>) but demonstrated a significant post hoc reduction in gram-positive deep infections without gram-negative shift. Mechanistic data indicate that sub-inhibitory vancomycin concentrations increase <i>Staphylococcus aureus</i&gt; biofilm formation and raise infection rates in vivo &amp;#8211; an effect not reproduced by cefazolin. Current international guidance does not issue a general recommendation for topical vancomycin, a position consistent with this more differentiated evidence base. The present review integrates these strands into an indication-specific framework that separates prophylactic application in clean surgical fields, where benefit is now in serious doubt, from adjunctive-therapeutic application in established infection, and identifies the settings in which topical vancomycin may still be considered individually and those in which it should be avoided.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-12T22:29:57+02:00</published>
            <updated>2026-06-12T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-337-2026</id>
            <title type="html">&#8220;ID-ing&#8221; the value: how are orthopaedic infectious  disease physicians compensated  for their time? A national survey
            </title>
            <link href="https://doi.org/10.5194/jbji-11-337-2026"/>
            <summary type="html">
                &lt;b&gt;“ID-ing” the value: how are orthopaedic infectious  disease physicians compensated  for their time? A national survey&lt;/b&gt;&lt;br&gt;
                Jessica C. O'Neil, Bethany Lehman, Thorsten Seyler, Nicolas Piuzzi, Sean Ryan, Jessica Seidelman, Julie Reznicek, and Poorani Sekar&lt;br&gt;
                    J. Bone Joint Infect., 11, 337&#8211;342, https://doi.org/10.5194/jbji-11-337-2026, 2026&lt;br&gt;
                We surveyed physicians in the United States who specialize in bone and joint infections to better understand how their work is financially supported. Most respondents reported spending substantial time on patient coordination, education, and multidisciplinary planning that was not directly reimbursed or protected by dedicated funding. These findings suggest current payment models may not adequately support the complex team-based care required for serious orthopedic infections.
            </summary>
            <content type="html">
                &lt;b&gt;“ID-ing” the value: how are orthopaedic infectious  disease physicians compensated  for their time? A national survey&lt;/b&gt;&lt;br&gt;
                Jessica C. O'Neil, Bethany Lehman, Thorsten Seyler, Nicolas Piuzzi, Sean Ryan, Jessica Seidelman, Julie Reznicek, and Poorani Sekar&lt;br&gt;
                    J. Bone Joint Infect., 11, 337&#8211;342, https://doi.org/10.5194/jbji-11-337-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>: Optimal outcomes in periprosthetic joint infection&amp;#160;(PJI) and other complex orthopaedic infections depend on longitudinal, multidisciplinary input from infectious disease&amp;#160;(ID) specialists. Much of this work is not directly billable, and the financial structures that support it have not been systematically described in any healthcare system. <strong>Methods</strong>: We distributed an anonymous online cross-sectional survey to ID&amp;#160;physician members of the Musculoskeletal Infection Society&amp;#160;(MSIS) and the Infectious Diseases Society of America Bone and Joint Interest&amp;#160;(IDSA-BOJO) group between 12&amp;#160;December&amp;#160;2025 and 30&amp;#160;January&amp;#160;2026. The survey captured practice setting, clinical and non-clinical orthopaedic&amp;#160;ID responsibilities, and sources of compensation and protected time. Data were analysed descriptively; no inferential statistical testing was performed. <strong>Results</strong>: Fifty-two&amp;#160;ID physicians responded, 94&amp;#8201;% from US&amp;#160;academic medical centres. Median&amp;#160;ID clinical effort was 70&amp;#8201;% (IQR 60&amp;#8201;%&amp;#8211;81&amp;#8201;%); of this, a median of 55&amp;#8201;% (IQR 40&amp;#8201;%&amp;#8211;90&amp;#8201;%) was devoted to orthopaedic infections. Compensation was most commonly a base salary plus productivity incentives (53&amp;#8201;%) or base salary alone (40&amp;#8201;%) and was funded by medicine/ID in 88&amp;#8201;% of cases. Care coordination (90&amp;#8201;%), curbside consultation (85&amp;#8201;%), trainee education (77&amp;#8201;%), and guideline development (71&amp;#8201;%) were performed; 83&amp;#8201;% of respondents received no protected time or dedicated funding for any of these non-billable activities. <strong>Conclusions</strong>: In this descriptive, hypothesis-generating national survey of highly subspecialized US&amp;#160;ID&amp;#160;physicians, compensation structures were dominated by clinical productivity and rarely included protected time for the non-billable coordination work that underpins modern multidisciplinary PJI care. These findings should be interpreted in the context of a small, academic-predominant sample and of substantial international variation in healthcare financing, and they support the need for larger international studies of how orthopaedic&amp;#160;ID expertise is funded and protected.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-12T22:29:57+02:00</published>
            <updated>2026-06-12T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-331-2026</id>
            <title type="html">Primary hip or knee arthroplasty in the setting of chronic suppressive antibiotics for prior periprosthetic joint infection: a scoping review
            </title>
            <link href="https://doi.org/10.5194/jbji-11-331-2026"/>
            <summary type="html">
                &lt;b&gt;Primary hip or knee arthroplasty in the setting of chronic suppressive antibiotics for prior periprosthetic joint infection: a scoping review&lt;/b&gt;&lt;br&gt;
                Vincent K. Melemai, Ryan J. Blake, Christian Barill, Adam E. Klein, Matthew J. Dietz, and Allison M. Lastinger&lt;br&gt;
                    J. Bone Joint Infect., 11, 331&#8211;336, https://doi.org/10.5194/jbji-11-331-2026, 2026&lt;br&gt;
                Total joint arthroplasty is increasingly common in the US, with an expected rise in periprosthetic joint infection (PJI). Limited evidence exists of PJI risk in new primary arthroplasty in patients on chronic suppression for prior PJI. Due to a lack of evidence examining this population, shared decision-making must be informed by medical comorbidities and patient-related risk factors, infectious history, and the current evidence of PJI treatment and infection control measures.
            </summary>
            <content type="html">
                &lt;b&gt;Primary hip or knee arthroplasty in the setting of chronic suppressive antibiotics for prior periprosthetic joint infection: a scoping review&lt;/b&gt;&lt;br&gt;
                Vincent K. Melemai, Ryan J. Blake, Christian Barill, Adam E. Klein, Matthew J. Dietz, and Allison M. Lastinger&lt;br&gt;
                    J. Bone Joint Infect., 11, 331&#8211;336, https://doi.org/10.5194/jbji-11-331-2026, 2026&lt;br&gt;
                <p><strong>Background:</strong&gt; Total joint arthroplasty (TJA) is an increasingly common intervention in the US, with an expected proportionate rise in periprosthetic joint infection (PJI). As part of the treatment plan, long-term suppressive oral antibiotic therapy is sometimes used in patients who would not benefit from further surgical intervention of their PJI. The aim of this scoping review is to outline the current evidence surrounding PJI incidence in new primary arthroplasty in this patient population. <strong>Methods:</strong&gt; A search was conducted using the PubMed and Scopus databases with no date restrictions. Studies examining the incidence of developing a PJI after new primary hip or knee arthroplasty in patients receiving chronic suppressive antibiotic therapy for a prior PJI were included. Two authors independently screened the results for inclusion in this review. <strong>Results:</strong&gt; Three retrospective cohort studies were ultimately included. Across studies, 61 patients with prior PJI receiving chronic suppressive antibiotics undergoing new primary TJA were identified. PJI rates in suppressed patients ranged from 0&amp;#8201;% to 21.4&amp;#8201;% compared to 0&amp;#8201;% to 2.9&amp;#8201;% in non-suppressed patients with prior PJI and 0&amp;#8201;% to 2.6&amp;#8201;% in matched controls without prior PJI. <strong>Conclusion:</strong&gt; Limited evidence exists regarding PJI risk in new primary arthroplasty among patients on chronic suppression for prior PJI, with a wide range of incidence reported across studies. Due to a lack of direct evidence examining this specific patient population, further research must be conducted in order to support strong recommendations.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-05T22:29:57+02:00</published>
            <updated>2026-06-05T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-323-2026</id>
            <title type="html">High intra- and inter-observer reliability of the PJI-TNM classification in acute and chronic periprosthetic  hip joint infection
            </title>
            <link href="https://doi.org/10.5194/jbji-11-323-2026"/>
            <summary type="html">
                &lt;b&gt;High intra- and inter-observer reliability of the PJI-TNM classification in acute and chronic periprosthetic  hip joint infection&lt;/b&gt;&lt;br&gt;
                Dominic Simon, Jonas Tumler, Lennart M. Schroeder, Florian Pachmann, Eduardo Suero, Boris M. Holzapfel, Gautier Beckers, and Kathrin Pfahl&lt;br&gt;
                    J. Bone Joint Infect., 11, 323&#8211;330, https://doi.org/10.5194/jbji-11-323-2026, 2026&lt;br&gt;
                <span data-olk-copy-source="MessageBody">This study assessed the reliability of the tumor, node, and metastasis (TNM) classification for periprosthetic joint infection (PJI) in patients with acute and chronic infections after hip replacement. Using a large clinical cohort, we found that clinicians with different levels of experience applied the system consistently. These findings support its use for describing disease severity, improving communication, and supporting future research and treatment planning.</span>
            </summary>
            <content type="html">
                &lt;b&gt;High intra- and inter-observer reliability of the PJI-TNM classification in acute and chronic periprosthetic  hip joint infection&lt;/b&gt;&lt;br&gt;
                Dominic Simon, Jonas Tumler, Lennart M. Schroeder, Florian Pachmann, Eduardo Suero, Boris M. Holzapfel, Gautier Beckers, and Kathrin Pfahl&lt;br&gt;
                    J. Bone Joint Infect., 11, 323&#8211;330, https://doi.org/10.5194/jbji-11-323-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>: Periprosthetic joint infections (PJIs) remain a significant complication following total hip arthroplasties (THAs), affecting patient outcomes and healthcare costs. The accurate classification of PJIs is crucial for guiding treatment decisions and improving patient management. The TNM classification system, commonly used in oncology, has previously been adapted for PJI to enhance our understanding of infection severity and is progressively used as PJI-TNM. <strong>Purpose</strong>: This study evaluates the applicability of the PJI-TNM classification in a cohort of 185 periprosthetic hip joint infections, including 84 acute and 101 chronic cases. <strong>Methods</strong>: In this retrospective study, we analyzed 84 cases of acute and 101 cases of chronic periprosthetic hip joint infections. Each case was independently classified according to the PJI-TNM framework by three observers. A second round of scoring was performed 90&amp;#8201;d later to assess the intra-observer concordance. The objective was to evaluate the utility of this classification in distinguishing between acute and chronic infections, predicting outcomes, and informing treatment strategies. Furthermore, intra- and inter-observer reliability were evaluated. <strong>Results</strong>: For acute PJIs we found a high inter-observer and intra-observer reliability for both the first and second evaluation (<span class="inline-formula"><i>&amp;#954;</i></span>&amp;#8201;0.78 and 0.89, respectively). In addition, the intra-observer analysis showed a very good correlation (<span class="inline-formula"><i>&amp;#954;</i></span>&amp;#8201;0.86&amp;#8211;0.96). For chronic PJIs the intra-observer reliability was <span class="inline-formula"><i>&amp;#954;</i></span&gt; of 0.85&amp;#8211;0.96, whereas inter-observer reliability was lower with <span class="inline-formula"><i>&amp;#954;</i></span&gt; of 0.75&amp;#8211;0.85. <strong>Conclusion</strong>: The PJI-TNM classification demonstrated strong intra-observer and substantial inter-observer reliability across both acute and chronic infections, supporting its use as a robust and reproducible framework for PJI classification.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-04T22:29:57+02:00</published>
            <updated>2026-06-04T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-315-2026</id>
            <title type="html">Tapping our resources: do preoperative  aspirations add diagnostic value in hip  and knee periprosthetic joint infection?
            </title>
            <link href="https://doi.org/10.5194/jbji-11-315-2026"/>
            <summary type="html">
                &lt;b&gt;Tapping our resources: do preoperative  aspirations add diagnostic value in hip  and knee periprosthetic joint infection?&lt;/b&gt;&lt;br&gt;
                Anne Spichler-Moffarah, Lauren Daddi, Ilda Molloy, Tyler Luu, Duc Nguyen, and Marjorie Golden&lt;br&gt;
                    J. Bone Joint Infect., 11, 315&#8211;321, https://doi.org/10.5194/jbji-11-315-2026, 2026&lt;br&gt;
                This is a study that included our daily practice with a cohort of patients with prosthetic joint infection (PJI) of the knee or hip, that had admissions with concern for PJI, and had surgery for that. Synovial aspiration and cultures were compared with intraoperative culture results. Our concordance rate (yielding the same organism(s) or if both were negative) between synovial and intraoperative cultures was almost 75 %, with low frequency of culture-negative and few polymicrobial PJI.&amp;#160;&amp;#160;
            </summary>
            <content type="html">
                &lt;b&gt;Tapping our resources: do preoperative  aspirations add diagnostic value in hip  and knee periprosthetic joint infection?&lt;/b&gt;&lt;br&gt;
                Anne Spichler-Moffarah, Lauren Daddi, Ilda Molloy, Tyler Luu, Duc Nguyen, and Marjorie Golden&lt;br&gt;
                    J. Bone Joint Infect., 11, 315&#8211;321, https://doi.org/10.5194/jbji-11-315-2026, 2026&lt;br&gt;
                <p><strong>Background</strong>: Discrepancies exist between preoperative synovial aspirations and intraoperative cultures. It is unclear whether the results of preoperative arthrocentesis add diagnostic value for patients with possible prosthetic joint infection&amp;#160;(PJI). <strong>Methods</strong>: We retrospectively identified adult patients treated surgically for hip and knee PJI who underwent both preoperative aspiration and intraoperative sampling. Synovial and intraoperative culture results were analyzed. Cultures were defined as concordant if they yielded the same organism(s) or if both were negative. Cultures were considered to be discordant if different organisms were isolated or if one had growth and the other was sterile. Demographic, clinical, and laboratory variables between groups were compared. <strong>Results</strong>: Among 75&amp;#160;patients, 54&amp;#160;(72&amp;#8201;%) had concordant results, and 21&amp;#160;(28&amp;#8201;%) had discordant results. In the discordant group, 7&amp;#160;of 21&amp;#160;patients (33&amp;#8201;%) had negative synovial cultures with positive intraoperative cultures. Among culture-positive concordant patients, staphylococci and streptococci were the most common isolates, with 20&amp;#8201;% gram negatives. True culture-negative PJI was uncommon (<span class="inline-formula"><i>n</i>=1</span>). Preoperative antibiotic exposure was frequent (<span class="inline-formula">>50</span>&amp;#8201;%) in both groups. <strong>Conclusion</strong>: In a cohort of hip and knee PJI patients treated surgically, preoperative synovial aspiration cultures were concordant with intraoperative cultures in 72&amp;#8201;% of cases, but negative synovial aspirations did not reliably exclude infection. Given the observed discordance, our findings support the obtainment of preoperative synovial aspiration and the collection of multiple intraoperative specimens at the time of surgery.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-06-03T22:29:57+02:00</published>
            <updated>2026-06-03T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-305-2026</id>
            <title type="html">Sinus tract and purulence as clinical criteria for periprosthetic joint infection: diagnostic accuracy, microorganisms, and clinical outcomes
            </title>
            <link href="https://doi.org/10.5194/jbji-11-305-2026"/>
            <summary type="html">
                &lt;b&gt;Sinus tract and purulence as clinical criteria for periprosthetic joint infection: diagnostic accuracy, microorganisms, and clinical outcomes&lt;/b&gt;&lt;br&gt;
                Markus Luger, Martin McNally, Lukas Rabitsch, Reinhard Windhager, Richard Lass, and Irene Katharina Sigmund&lt;br&gt;
                    J. Bone Joint Infect., 11, 305&#8211;313, https://doi.org/10.5194/jbji-11-305-2026, 2026&lt;br&gt;
                Sinus tracts communicating with the prosthesis demonstrated high specificity and support their use as a confirmatory criterion for periprosthetic joint infection (PJI). Purulence also showed high specificity but may be better considered to be a suggestive criterion due to challenges in clinical differentiation. Both findings were associated with distinct microbiological patterns and less favourable outcomes, highlighting their clinical relevance.
            </summary>
            <content type="html">
                &lt;b&gt;Sinus tract and purulence as clinical criteria for periprosthetic joint infection: diagnostic accuracy, microorganisms, and clinical outcomes&lt;/b&gt;&lt;br&gt;
                Markus Luger, Martin McNally, Lukas Rabitsch, Reinhard Windhager, Richard Lass, and Irene Katharina Sigmund&lt;br&gt;
                    J. Bone Joint Infect., 11, 305&#8211;313, https://doi.org/10.5194/jbji-11-305-2026, 2026&lt;br&gt;
                <p><strong>Introduction</strong>: Clinical criteria are included in all current periprosthetic joint infection (PJI) definitions, with sinus tract and purulence among the most unequivocal indicators of infection. However, evidence regarding their diagnostic accuracy remains limited. This study evaluated their diagnostic performance, associated microbial profile, and clinical outcomes. <strong>Methods</strong>: This retrospective study included 463 revision hip and knee arthroplasties between 2015 and 2023. A total of 245 (52.9&amp;#8201;%) were classified as infected according to the 2021 European Bone and Joint Infection Society (EBJIS) definition. Receiver-operating-characteristic (ROC) curves and their areas under the curve (AUCs) were used for diagnostic accuracy calculations. Follow-up analysis was conducted using the Kaplan&amp;#8211;Meier survival estimator. <strong>Results</strong>: Sensitivities for sinus tract and purulence were 12.7&amp;#8201;% (95&amp;#8201;% CI: 8.8&amp;#8211;17.5) and 35.1&amp;#8201;% (29.1&amp;#8211;41.4), with specificities of 100&amp;#8201;% (98.3&amp;#8211;100) for both. AUCs were 0.546 (0.521&amp;#8211;0.571) and 0.695 (0.653&amp;#8211;0.737). The highest prevalence of sinus tract was observed in <i>Candida albicans</i&gt; (50&amp;#8201;%), polymicrobial infection (33&amp;#8201;%), and <i>Cutibacterium acnes</i&gt; (30&amp;#8201;%), whereas purulence was most prevalent in <i>Streptococcus</i&gt; spp. (73&amp;#8201;%), <i>Staphylococcus aureus</i&gt; (72&amp;#8201;%), Enterobacteriaceae (50&amp;#8201;%), and polymicrobial infections (43&amp;#8201;%). Both were associated with lower 3-year infection-free survival; this was significant for sinus tract (<span class="inline-formula"><i>p</i>=0.011</span>) and showed a trend for purulence (<span class="inline-formula"><i>p</i>=0.068</span>). <strong>Conclusion</strong>: A sinus tract can be considered a confirmatory criterion for PJI due to its excellent specificity. Although highly specific, purulence remains subjective, with limited sensitivity, and should, if considered, be regarded only as a suggestive criterion. Both parameters were associated with lower survival rates and a consistent trend towards treatment failure.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-05-29T22:29:57+02:00</published>
            <updated>2026-05-29T22:29:57+02:00</updated>
        </entry>
        <entry>
            <id>https://doi.org/10.5194/jbji-11-299-2026</id>
            <title type="html">Nasal decolonization in total joint arthroplasty:  current state of evidence
            </title>
            <link href="https://doi.org/10.5194/jbji-11-299-2026"/>
            <summary type="html">
                &lt;b&gt;Nasal decolonization in total joint arthroplasty:  current state of evidence&lt;/b&gt;&lt;br&gt;
                Andrea Zampoli, Ghazal Pourbozorg, Goksel Dikmen, Ibrahim Tuncay, and Javad Parvizi&lt;br&gt;
                    J. Bone Joint Infect., 11, 299&#8211;304, https://doi.org/10.5194/jbji-11-299-2026, 2026&lt;br&gt;
                <em>Staphylococcus aureus</em&gt; nasal colonization is a key contributor to postoperative infection after hip and knee replacement. We review current evidence on screening and nasal decolonization, highlighting that reliable decolonization is more critical than screening alone. We summarize practical treatment options and propose a simple, standardized preoperative protocol that can be implemented in routine arthroplasty pathways to reduce preventable infections.
            </summary>
            <content type="html">
                &lt;b&gt;Nasal decolonization in total joint arthroplasty:  current state of evidence&lt;/b&gt;&lt;br&gt;
                Andrea Zampoli, Ghazal Pourbozorg, Goksel Dikmen, Ibrahim Tuncay, and Javad Parvizi&lt;br&gt;
                    J. Bone Joint Infect., 11, 299&#8211;304, https://doi.org/10.5194/jbji-11-299-2026, 2026&lt;br&gt;
                <p>Periprosthetic joint infection is a major cause of morbidity and economic cost after total joint arthroplasty, with <i>Staphylococcus aureus</i&gt; consistently identified as the most common pathogen causing surgical site infection (SSI) and periprosthetic joint infections (PJIs). Nasal mucosa is one of the principle reservoirs for <i>S. aureus</i>. Molecular epidemiology investigations have found concordance between nasal organisms and infecting strains, implying that many postoperative infections arise endogenously. Over the last decade, various clinical trials, institutional protocols, and meta-analyses have evaluated the efficacy of nasal screening and decolonization of <i>Staph aureus</i>. Recent evidence suggests that the success of infection prevention procedures is dependent on the reliability and consistency of decolonization rather than screening alone. This narrative review summarizes current evidence&amp;#160;on nasal decolonization in total joint arthroplasty, including epidemiological data, methods of screening, and accessible therapy choices to suggest practical and reproducible infection control measures.</p>
            </content>
            <author>
                <name>Copernicus Electronic Production Support Office</name>
            </author>
            <published>2026-05-22T22:29:57+02:00</published>
            <updated>2026-05-22T22:29:57+02:00</updated>
        </entry>
</feed>